Poseida Therapeutics is a clinical-stage biopharmaceutical company engaged in utilizing its proprietary gene engineering platform technologies to create next generation cell and gene therapeutics. Co. maintains a portfolio of product candidates based on its core proprietary platforms, including the non-viral piggyBac DNA Modification System, Cas-CLOVER site-specific gene editing system and nanoparticle- and AAV-based gene delivery technologies. Co.'s platform technologies has uses across cell and gene therapeutic modalities that enables Co. to engineer its portfolio of product candidates that are designed to overcome the primary limitations of generation cell and gene therapeutics. The PSTX stock yearly return is shown above.
The yearly return on the PSTX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the PSTX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|